Effect of glutamine supplementation on cardiovascular risk factors in patients with type 2 diabetes

Nutrition

Volumn 31, Issue 1, 2015, Pages 119-126

  Mansour, Asieh ^a,b   Mohajeri Tehrani, Mohammad Reza ^b   Qorbani, Mostafa ^c,d   Heshmat, Ramin ^b   Larijani, Bagher ^b   Hosseini, Saeed ^b  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ALBORZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Body composition; GLP 1; Glutamine supplementation; Insulin; Type 2 diabetes

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUTAMINE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; ARTICLE; BODY FAT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DIET SUPPLEMENTATION; DISEASE ASSESSMENT; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE; HUMAN; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TRUNK; WAIST CIRCUMFERENCE; ADIPOSE TISSUE; BLOOD; BLOOD PRESSURE; BODY COMPOSITION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIET; DIETARY SUPPLEMENT; DOSE RESPONSE; DRUG EFFECTS; INSULIN RESISTANCE; METABOLISM; MIDDLE AGED; MOTOR ACTIVITY; RISK FACTOR;

ADIPOSE TISSUE; ADULT; BLOOD GLUCOSE; BLOOD PRESSURE; BODY COMPOSITION; BODY MASS INDEX; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DIET; DIETARY SUPPLEMENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GLUTAMINE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; MOTOR ACTIVITY; RISK FACTORS; TRIGLYCERIDES;

EID: 84922242219     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2014.05.014     Document Type: Article

References (51)

1. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011, 7:S5-S10. American Diabetes Association.
2. Crochemore I.C.C., Souza A.F., de Souza A.C., Rosado E.L. ω-3 Polyunsaturated fatty acid supplementation does not influence body composition, insulin resistance, and lipemia in women with type 2-diabetes and obesity. Nutr Clin Pract 2012, 27:553-560.
3. Kelly T.N., Bazzano L.A., Fonseca V.A., Thethi T.K., Reynolds K., He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:394-403.
4. Curtis P.J., Sampson M., Potter J., Dhatariya K., Kroon P.A., Cassidy A. Chronic ingestion of flavan-3-ols and isoflavones improves insulin sensitivity and lipoprotein status and attenuates estimated 10-year CVD risk in medicated postmenopausal women with type 2-diabetes: a 1-year, double-blind, randomized, controlled trial. Diabetes Care 2012, 35:226-232.
5. Blaha M.J., Gebretsadik T., Shintani A., Elasy T.A. Waist circumference, not the metabolic syndrome, predicts glucose deterioration in type 2 diabetes. Obesity 2008, 16:869-874.
6. Arathuzik G.G., Goebel-Fabbri A.E. Nutrition therapy and the management of obesity and diabetes: An update. Curr Diabetes Rep 2011, 11:106-110.
7. Wing R.R., Lang W., Wadden T.A., Safford M., Knowler W.C., Bertoni A.G., et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011, 34:1481-1486.
8. Kim T.N., Park M.S., Yang SJ, Yoo H.J., Kang H.J., Song W., et al. Prevalence and determinant factors of aarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS). Diabetes Care 2010, 33:1497-1499.
9. Lee C.G., Boyko E.J., Strotmeyer E.S., Lewis C.E., Cawthon P.M., Hoffman A.R., et al. Association between insulin resistance and lean mass loss and fat mass gain in older men without diabetes mellitus. J Am Geriatr Soc 2011, 59:1217-1224.
10. Park S.W., Goodpaster B.H., Lee J.S., Kuller L.H., Boudreau R., de Rekeneire N., et al. Excessive loss of skeletal muscle mass in older adults with type 2 diabetes. Diabetes Care 2009, 32:1993-1997.
11. Wernerman J. Clinical use of glutamine supplementation. J Nutr 2008, 138:2040 S-2044 S.
12. Savarese D.M., Savy G., Vahdat L., Wischmeyer P.E., Corey B. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treat Rev 2003, 29:501-514.
13. Tsai P.H., Liu J.J., Chiu W.C., Pai M.H., Yeh S.L. Effects of dietary glutamine on adhesion molecule expression and oxidative stress in mice with streptozotocin-induced type 1 diabetes. Clin Nutr 2011, 30:124-129.
14. Boza J.J., Turini M., Moënnoz D., Montigon F., Vuichoud J., Gueissaz N., et al. Effect of glutamine supplementation of the diet on tissue protein synthesis rate of glucocorticoid-treated rats. Nutrition 2001, 17:35-40.
15. Holeček M., Skopec F., Skalská H., Šprongl L. Effect of alanyl-glutamine on leucine and protein metabolism in endotoxemic rats. J Parenter Enteral Nutr 2000, 24:215-222.
16. Opara E.C., Petro A., Tevrizian A., Feinglos M.N., Surwit R.S. L-glutamine supplementation of a high fat diet reduces body weight and attenuates hyperglycemia and hyperinsulinemia in C57 BL/6 J mice. J Nutr 1996, 126:273.
17. Greenfield J.R., Farooqi I.S., Keogh J.M., Henning E., Habib A.M., Blackwood A., et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr 2009, 89:106-113.
18. Samocha-Bonet D., Wong O., Synnott E.-L., Piyaratna N., Douglas A., Gribble F.M., et al. Glutamine reduces postprandial glycemia and augments the glucagon-like peptide-1 response in type 2 diabetes patients. J Nutr 2011, 141:1233-1238.
19. Kyle U.G., Bosaeus I., De Lorenzo A.D., Deurenberg P., Elia M., Gómez J.M., et al. Bioelectrical impedance analysis-part I: review of principles and methods. Clin Nutr 2004, 23:1226-1243.
20. Craig C.L., Marshall A.L., Sjöström M., Booth M.L., Ainsworth B.E., Pratt M., et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc 2003, 35:1381-1395.
21. Matthews D., Hosker J., Rudenski A., Naylor B., Treacher D., Turner R. Homeostasis model assessment: Insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28:412-419.
22. Katz A., Nambi S.S., Mather K., Baron A.D., Follmann D.A., Sullivan G., et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000, 85:2402-2410.
23. Prada P., Hirabara S., de Souza C.T., Schenka A.A., Zecchin H.G., Vassallo J., et al. L-glutamine supplementation induces insulin resistance in adipose tissue and improves insulin signaling in liver and muscle of rats with diet-induced obesity. Diabetologia 2007, 50:1949-1959.
24. Bouché C., Rizkalla S.W., Luo J., Vidal H., Veronese A., Pacher N., et al. Five-week, low-glycemic index diet decreases total fat mass and improves plasma lipid profile in moderately overweight nondiabetic men. Diabetes Care 2002, 25:822-828.
25. Gin H., Rigalleau V., Perlemoine C. Insulin therapy and body weight, body composition and muscular strength in patients with type 2 diabetes mellitus. J Nutr Metab 2010, 2010. 10.1155/2010/340570.
26. Lee J., Auyeung T., Leung J., Kwok T., Leung P., Woo J. The effect of diabetes mellitus on age-associated lean mass loss in 3153 older adults. Diabet Med 2010, 27:1366-1371.
27. Solerte S.B., Gazzaruso C., Bonacasa R., Rondanelli M., Zamboni M., Basso C., et al. Nutritional supplements with oral amino acid mixtures increases whole-body lean mass and insulin sensitivity in elderly subjects with sarcopenia. Am J Cardiol 2008, 101:S69-S77.
28. Haan M.N., Mungas D.M., Gonzalez H.M., Ortiz T.A., Acharya A., Jagust W.J. Prevalence of dementia in older Latinos: the influence of type 2 diabetes mellitus, stroke and genetic factors. J Am Geriatr Soc 2003, 51:169-177.
29. Tong J., Sandoval D.A. Is the GLP-1 system a viable therapeutic target for weight reduction?. Rev Endocr Metab Disord 2011, 12:187-195.
30. Mansour A., Hosseini S., Larijani B., Pajouhi M., Mohajeri-Tehrani M.R. Nutrients related to GLP1 secretory responses. Nutrition 2013, 29:813-820.
31. Poirier P., Giles T.D., Bray G.A., Hong Y., Stern J.S., Pi-Sunyer F.X., et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006, 113:898-918.
32. Lazzer S., Boirie Y., Montaurier C., Vernet J., Meyer M., Vermorel M. A weight reduction program preserves fat-free mass but not metabolic rate in obese adolescents. Obes Res 2004, 12:233-240.
33. Noreen E.E., Sass M.J., Crowe M.L., Pabon V.A., Brandauer J., Averill L.K. Effects of supplemental fish oil on resting metabolic rate, body composition, and salivary cortisol in healthy adults. Jissn 2010, 7. 10.1186.
34. Robinson L.E., Holt T.A., Rees K., Randeva H.S., O'Hare J.P. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open 2013, 3.
35. Henquin J.-C., Dufrane D., Nenquin M. Nutrient control of insulin secretion in isolated normal human islets. Diabetes 2006, 55:3470-3477.
36. Bakalar B., Duska F., Pachl J., Fric M., Otahal M., Pazout J., et al. Parenterally administered dipeptide alanyl-glutamine prevents worsening of insulin sensitivity in multiple-trauma patients. Crit Care Med 2006, 34:381-386.
37. Reimann F., Williams L., da Silva Xavier G., Rutter G., Gribble F. Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia 2004, 47:1592-1601.
38. Kjems L.L., Holst J.J., Vølund A., Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion effects on β-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52:380-386.
39. Holst J.J., Christensen M., Lund A., de Heer J., Svendsen B., Kielgast U., et al. Regulation of glucagon secretion by incretins. Diabetes Obes Metab 2011, 13:89-94.
40. Norris L.E., Collene A.L., Asp M.L., Hsu J.C., Liu L.F., Richardson J.R., et al. Comparison of dietary conjugated linoleic acid with safflower oil on body composition in obese postmenopausal women with type 2 diabetes mellitus. Am J Clin Nutr 2009, 90:468-476.
41. Tsai P.H., Yeh C.L., Liu J.J., Chiu W.C., Yeh S.L. Effects of dietary glutamine on inflammatory mediator gene expressions in rats with streptozotocin-induced diabetes. Nutrition 2012, 28:288-293.
42. Bastard J.P., Maachi M., Lagathu C., Kim M.J., Caron M., Vidal H., et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
43. Galera S.C., Fechine F., Teixeira M.J., Coelho Z.C.B., de Vasconcelos R.C., Leitão de Vasconcelos P.R. The safety of oral use of L-glutamine in middle-aged and elderly individuals. Nutrition 2010, 26:375-381.
44. Leenders M., Verdijk L.B., van der Hoeven L., van Kranenburg J., Hartgens F., Wodzig W.K., et al. Prolonged leucine supplementation does not augment muscle mass or affect glycemic control in elderly type 2 diabetic men. JNutr 2011, 141:1070-1076.
45. Van Acker B.A., Hulsewé K.W., Wagenmakers A.J., von Meyenfeldt M.F., Soeters P.B. Response of glutamine metabolism-glutamine-supplemented parenteral nutrition. Am Clin Nutr 2000, 72:790-795.
46. Wilmore D.W. The effect of glutamine supplementation in patients following elective surgery and accidental injury. J nutr 2001, 131:2543 S-2549 S.
47. Naseem K.M. The role of nitric oxide in cardiovascular diseases. Mol Aspects Med 2005, 26:33-65.
48. Vermeulen M.A., van de Poll M.C., Ligthart-Melis G.C., Dejong C.H., van den Tol M.P., Boelens P.G., et al. Specific amino acids in the critically ill patient-exogenous glutamine/arginine: A common denominator?. Crit Care Med 2007, 35:S568-S576.
49. Boelens P.G., van Leeuwen P.A., Dejong C.H., Deutz N.E. Intestinal renal metabolism of L-citrulline and L-arginine following enteral or parenteral infusion of L-alanyl-L-[2,15 N] glutamine or L-[2,15 N]glutamine in mice. Am J Physiol Gastrointest Liver Physiol 2005, 289:G679-G685.
50. Rennie K.L., Coward A., Jebb S.A. Estimating underreporting of energy intakein dietary surveys using an individualised method. Br J Nutr 2007, 97:1169-1176.
51. Hill R., Davies P. The validity of self-reported energy intake as determined using the doubly labeled water technique. Br J Nutr 2001, 85:415-430.